Status:
COMPLETED
Efficacy/Safety/Subject Satisfaction/Duration of Response of Clobetasol Propionate Spray vs Ointment in Plaque Psoriasis
Lead Sponsor:
Galderma R&D
Conditions:
Plaque Psoriasis
Eligibility:
All Genders
18-80 years
Phase:
PHASE4
Brief Summary
This study is a comparison between Clobetasol Propionate Spray and Clobetasol Propionate Ointment with Regard to Efficacy, Safety, Subject Satisfaction and Duration of Response in Moderate to Severe S...
Detailed Description
Same as above.
Eligibility Criteria
Inclusion
- Subjects with a diagnosis of moderate to severe plaque psoriasis, defined as 3% - 20% of the body surface area. For the purposes of study treatment, most areas will be treated with the exception of face, scalp, groin, axillae and other intertriginous areas
- Overall disease severity is at least 3 (moderate)
Exclusion
- Subjects who have surface area involvement too large that would require more than 50 grams per week of clobetasol propionate spray or more than 50 grams per week of clobetasol propionate ointment
- Subjects whose psoriasis involves only the scalp, face or groin
- Subjects with non-plaque psoriasis or other related diseases not classified as plaque psoriasis
Key Trial Info
Start Date :
August 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2008
Estimated Enrollment :
250 Patients enrolled
Trial Details
Trial ID
NCT00733954
Start Date
August 1 2007
End Date
April 1 2008
Last Update
August 23 2022
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
East Bay Dermatology Medical Group, Inc.
Fremont, California, United States, 94538
2
Solano Clinical Research
Vallejo, California, United States, 94589
3
Henry Ford Medical Center
Detroit, Michigan, United States, 48202
4
Minnesota Clinical Study Center
Fridley, Minnesota, United States, 55432